Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Mylan Pharmaceuticals Inc. v. United States Food and Drug Administration
Case Number:
1:14-cv-00075
Court:
Nature of Suit:
Judge:
District Judge Irene M. Keeley
Firms
- Axinn Veltrop
- Hyman Phelps
- Jackson Kelly PLLC
- Kirkland & Ellis
- Olsson Frank
- Shuman McCuskey
- Steptoe & Johnson PLLC
- Venable LLP
Companies
Government Agencies
Sectors & Industries:
-
June 02, 2014
Mylan Strikes Deal With Pfizer To Sell Generic Celebrex
Mylan Pharmaceuticals Inc. has reached a deal with Pfizer Inc. to allow it to begin selling generic versions of arthritis drug Celebrex by the end of the year, Mylan said in a statement Monday.
-
May 30, 2014
Teva Retains Inside Track To Market Generic Celebrex
Teva Pharmaceutical Industries Ltd. has kept exclusive rights to market its generic version of Pfizer Inc.'s arthritis drug Celebrex, as a West Virginia federal judge ruled Thursday that the U.S. Food and Drug Administration didn't overstep its bounds in denying an exclusivity share to other generic-drug makers.
-
April 28, 2014
Watson, Mylan Slam FDA Over Generic Celebrex Decision
Watson Laboratories Inc. and Mylan Pharmaceuticals Inc. hit the U.S. Food and Drug Administration with separate lawsuits Monday after the regulator determined another generic-drug maker still has exclusivity rights to market its version of Pfizer Inc.'s arthritis drug Celebrex.